Portfolio company
Athernal Bio
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops targeted immunotherapies for patients with high-risk clonal haematopoiesis to prevent the development of blood cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Appia Bio
This company develops engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients.
Asher Bio
The company develops cis-targeted immunotherapies that selectively activate specific immune cells to treat patients with cancer and other diseases.
Atavistik Bio
This biotechnology company develops oral allosteric small molecule therapeutics for patients with rare hematological diseases and cancers.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Alyssum Therapeutics
This company develops B cell-based targeted immunotherapies for patients with solid tumours and complex immunological conditions.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Abalos Therapeutics
This company develops arenavirus-based immuno-virotherapies to treat solid tumours and metastases for patients with cancer.